• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study: Sanofi’s diabetes drug brings earlier blood sugar control than insulin glargine

September 12, 2017 By Sarah Faulkner

SanofiA post-hoc analysis of two late-stage trials of Sanofi‘s (NYSE:SNY) Soliqua insulin glargine and lixisenatide injection showed that it provides blood sugar control earlier and in more adults than just insulin glargine, the company reported.

The analysis was presented today at the European Association for the Study of Diabetes in Portugal.

Researchers reviewed data from Phase III trials LixiLan-O and LixiLan-L, comparing the effectiveness of Soliqua and insulin glargine in more than 1,900 adults with Type II diabetes.

More adults using Sanofi’s Soliqua reached blood sugar targets at eight and 12 weeks compared to those receiving insulin glargine, the company said.

“Reaching an HbA1C target quickly can have a benefit for adults with type 2 diabetes,” Dr. Juan Frias, president & principal investigator of the National Research Institute, said in prepared remarks. “Early, effective glycemic control can lead to better outcomes, both clinically and in terms of the overall cost of care.”

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Clinical Trials, Diabetes, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Sanofi-Aventis

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS